Life-threatening coronary vasospasm in patients with type 2 diabetes with SGLT2 inhibitor-induced euglycemic ketoacidosis: a report of two consecutive cases
Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overwei...
Saved in:
| Published in | Diabetology international Vol. 15; no. 1; pp. 135 - 140 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Singapore
Springer Nature Singapore
01.01.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2190-1678 2190-1686 |
| DOI | 10.1007/s13340-023-00664-8 |
Cover
| Abstract | Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m
2
), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO
3
−
), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m
2
) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO
3
−
, 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA. |
|---|---|
| AbstractList | Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m
), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO
), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m
) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO
, 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA. Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m 2 ), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO 3 − ), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m 2 ) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO 3 − , 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA. Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m2), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO3−), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m2) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO3−, 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA. Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m2), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO3-), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m2) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO3-, 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA.Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m2), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO3-), 13.2 mmol/L; and total ketone body, 1539 µmol/L. Coronary angiography (CAG) performed on day 5 revealed diffusely spastic coronary arteries with 90% stenosis in the right coronary artery, leading to the diagnosis of VSA in the presence of coronary atherosclerosis. Case 2: A 63-year-old male patient with type 2 diabetes (BMI 22.2 kg/m2) experienced severe chest discomfort and faintness following 2 months of chest pain while on dapagliflozin 10 mg daily for 1 year: plasma glucose, 112 mg/dL; urine ketones, (+++); HCO3-, 15.3 mmol/L; and total ketone body, 10,883 µmol/L. CAG performed on day 10 revealed no organic stenosis but diffusely spastic coronary arteries in response to coronary ergonovine infusion, confirming the diagnosis of VSA. SGLT2i has the potential to inhibit acetylcholine and butyrylcholine esterase activities, leading to reduced scavenging of acetylcholine and possible induction of coronary vasospasm. These cases highlight the association between life-threatening VSA and SGLT2i-induced eDKA. |
| Author | Yagi, Kunimasa Takata, Hiroyuki Kawahara, Junko Kitagawa, Naotaka Wakabayashi, Yusuke Senda, Satoko Kaku, Bunji Hiraiwa, Yoshio Yokoyama, Maki |
| Author_xml | – sequence: 1 givenname: Junko surname: Kawahara fullname: Kawahara, Junko organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 2 givenname: Bunji surname: Kaku fullname: Kaku, Bunji organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 3 givenname: Kunimasa orcidid: 0000-0002-6805-6428 surname: Yagi fullname: Yagi, Kunimasa email: yagikuni@icloud.com organization: Department of Internal Medicine, Kanazawa Medical University Hospital – sequence: 4 givenname: Naotaka surname: Kitagawa fullname: Kitagawa, Naotaka organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 5 givenname: Maki surname: Yokoyama fullname: Yokoyama, Maki organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 6 givenname: Yusuke surname: Wakabayashi fullname: Wakabayashi, Yusuke organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 7 givenname: Satoko surname: Senda fullname: Senda, Satoko organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 8 givenname: Hiroyuki surname: Takata fullname: Takata, Hiroyuki organization: Department of Internal Medicine, Toyama Red Cross Hospital – sequence: 9 givenname: Yoshio surname: Hiraiwa fullname: Hiraiwa, Yoshio organization: Department of Internal Medicine, Toyama Red Cross Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38264228$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksuOFCEUhitmjDOO8wIuDIkbN6VAUVzcGDPR0aQTF45rQlGnuhmroASqJ_0uPqy03baXhSQEAt9_LvA_rs588FBVTwl-STAWrxJpGoZrTJsaY85ZLR9UF5QoXBMu-dlpL-R5dZXSHS6DKYIFf1SdN5JyRqm8qL6v3AB13kQwGbzza2RDDN7EHdqaFNJs0oScR7PJDnxO6N7lDcq7GRBFvTMdZDgefr5Z3dLCblzncoi18_1ioUewrMedhclZ9BVyMNb1Ibn0GhkUYQ4xozCgfB9KZp_ALtltAVmTID2pHg5mTHB1XC-rL-_f3V5_qFefbj5ev13Vtm1JroFiJlQnlBpaTCgzTDaKtZjLtiO254xYoBb3ALIb6CBEK3lvFWedFL1iTXNZvTnEnZdugt6WRqMZ9RzdVB5CB-P03zfebfQ6bDXBEuOGkhLhxTFCDN8WSFlPLlkYR-MhLElTRSRRXChZ0Of_oHdhib70t6dEmZi3hXr2Z0mnWn79XAHoAbAxpBRhOCEE671D9MEhujhE_3SI3ouagygV2K8h_s79H9UPHsTADA |
| Cites_doi | 10.1016/j.amjcard.2007.12.018 10.12659/AJCR.929773 10.1016/0735-1097(88)90449-4 10.2174/1573399816666200316112709 10.2337/dc23-S009 10.1097/CCM.0000000000003224 10.1016/j.ajem.2021.02.015 10.2337/dc22-0323 10.1253/circj.CJ-15-1202 10.1016/j.jjcc.2008.01.001 10.4103/1947-2714.157490 10.1161/01.cir.58.1.56 10.1186/s12902-017-0174-6 10.1161/CIRCULATIONAHA.111.037283 10.1056/NEJMoa1504720 10.1016/0002-9149(77)90060-1 10.1161/CIRCEP.110.959809 10.1016/j.acvd.2018.08.002 10.1161/01.cir.74.5.955 10.1016/j.jccase.2016.10.006 10.1016/j.cbi.2017.08.013 10.1620/tjem.255.291 10.4103/jfmpc.jfmpc_644_21 10.1620/tjem.141.suppl_479 10.1002/9781119309642.ch13 |
| ContentType | Journal Article |
| Copyright | The Japan Diabetes Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| Copyright_xml | – notice: The Japan Diabetes Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| DBID | AAYXX CITATION NPM K9. 7X8 5PM |
| DOI | 10.1007/s13340-023-00664-8 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2190-1686 |
| EndPage | 140 |
| ExternalDocumentID | PMC10800321 38264228 10_1007_s13340_023_00664_8 |
| Genre | Case Reports |
| GrantInformation_xml | – fundername: Japan Society for the Promotion of Science grantid: JP21K10300 funderid: http://dx.doi.org/10.13039/501100001691 |
| GroupedDBID | --- -EM 06C 06D 0R~ 0VY 203 29~ 2JY 2VQ 30V 4.4 406 408 409 96X AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAZMS ABAKF ABBXA ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACKNC ACMLO ACOKC ACPIV ACPRK ACZOJ ADHHG ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEMSY AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AKLTO AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH AUKKA AXYYD BGNMA CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD EN4 ESBYG FERAY FIGPU FINBP FNLPD FRRFC FSGXE FYJPI G-Y G-Z GGCAI GGRSB GJIRD GQ6 GQ7 GQ8 H13 HMJXF HQYDN HRMNR HYE HZ~ I0C IAO IHR IKXTQ INH ISR ITC IWAJR IXD IZIGR J-C J0Z JBSCW JCJTX JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O9- O93 O9I O9J OK1 P9S PT4 QOR QOS R89 R9I RLLFE ROL RPM RSV S1Z S27 S37 S3B SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 T13 TSG U2A U9L UG4 UOJIU UTJUX UZXMN VFIZW W48 WK8 Z45 Z87 ZMTXR ZOVNA ~A9 ~S- AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR CITATION ABRTQ NPM K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c551t-e20479b799f50124a4839450685b1cd641ce2c0dee8bf2f77586dc964b87d9433 |
| IEDL.DBID | U2A |
| ISSN | 2190-1678 |
| IngestDate | Thu Aug 21 18:30:21 EDT 2025 Fri Jul 11 01:29:59 EDT 2025 Wed Sep 10 04:57:17 EDT 2025 Mon Jul 21 05:39:13 EDT 2025 Tue Jul 01 02:33:01 EDT 2025 Fri Feb 21 02:41:36 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Acetylcholine Coronary vasospastic angina SGLT2 inhibitor Euglycemic diabetic ketoacidosis |
| Language | English |
| License | The Japan Diabetes Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c551t-e20479b799f50124a4839450685b1cd641ce2c0dee8bf2f77586dc964b87d9433 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0002-6805-6428 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/10800321 |
| PMID | 38264228 |
| PQID | 2917291065 |
| PQPubID | 2043937 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10800321 proquest_miscellaneous_2918196798 proquest_journals_2917291065 pubmed_primary_38264228 crossref_primary_10_1007_s13340_023_00664_8 springer_journals_10_1007_s13340_023_00664_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Singapore |
| PublicationPlace_xml | – name: Singapore – name: Japan – name: Heidelberg |
| PublicationTitle | Diabetology international |
| PublicationTitleAbbrev | Diabetol Int |
| PublicationTitleAlternate | Diabetol Int |
| PublicationYear | 2024 |
| Publisher | Springer Nature Singapore Springer Nature B.V |
| Publisher_xml | – name: Springer Nature Singapore – name: Springer Nature B.V |
| References | ElSayed, Aleppo, Aroda, Bannuru, Brown, Bruemmer (CR1) 2023; 46 Mousa, Sayed, Moussa, Hassan (CR13) 2017; 17 Dai, Nishihata, Kawamatsu, Komatsu, Mizuno, Shimizu (CR23) 2017; 15 Yasue, Horio, Nakamura, Fujii, Imoto, Sonoda (CR14) 1986; 74 Zinman, Wanner, Lachin, Fitchett, Bluhmki, Hantel (CR2) 2015; 373 CR18 Beltrame, Crea, Kaski, Ogawa, Ong, Sechtem (CR22) 2016; 80 Joffre, Bourcier, Hariri, Miailhe, Bige, Dumas (CR15) 2018; 46 (CR5) 2015; 7 Kageyama, Taniguchi, Tanaka, Tajima, Saito, Ikeda, Abe (CR16) 1983; 141 Picard, Sayah, Spagnoli, Adjedj, Varenne (CR8) 2019; 112 Okumura, Yasue, Matsuyama, Goto, Miyagi, Ogawa, Matsuyama (CR10) 1988; 12 Arafa, Ali, Hassan (CR12) 2017; 277 Schroeder, Bolen, Quint, Clark, Hayden, Higgins, Wexler (CR6) 1977; 40 Ohkubo, Kobayashi, Komuro (CR21) 2008; 101 Long, Lentz, Koyfman, Gottlieb (CR4) 2021; 44 Hashi, Fujiki, Yagi (CR19) 2021; 255 Lanza, Careri, Crea (CR7) 2011; 124 Yasue, Nakagawa, Itoh, Harada, Mizuno (CR17) 2008; 51 Yasue, Nagao, Omote, Takizawa, Miwa, Tanaka (CR20) 1978; 58 Dutta, Kumar, Singh, Ambwani, Charan, Varthya (CR3) 2022; 11 Xu, Zheng, Hou, Lin, Wang, Wang (CR11) 2022; 45 Goto, Ishikawa, Idei, Iwabuchi, Namekawa, Nomura (CR25) 2021; 22 Takagi, Yasuda, Tsunoda, Ogata, Seki, Sumiyoshi (CR9) 2011; 4 Dorcely, Nitis, Schwartzbard, Newman, Goldberg, Sum (CR24) 2021; 17 SO Mousa (664_CR13) 2017; 17 H Yasue (664_CR20) 1978; 58 B Zinman (664_CR2) 2015; 373 K Okumura (664_CR10) 1988; 12 H Yasue (664_CR14) 1986; 74 J Joffre (664_CR15) 2018; 46 B Long (664_CR4) 2021; 44 M Xu (664_CR11) 2022; 45 S Kageyama (664_CR16) 1983; 141 NA ElSayed (664_CR1) 2023; 46 H Yasue (664_CR17) 2008; 51 R Hashi (664_CR19) 2021; 255 F Picard (664_CR8) 2019; 112 Thawabi M, Studyvin S (664_CR5) 2015; 7 GA Lanza (664_CR7) 2011; 124 664_CR18 S Goto (664_CR25) 2021; 22 S Dutta (664_CR3) 2022; 11 Z Dai (664_CR23) 2017; 15 JF Beltrame (664_CR22) 2016; 80 NMS Arafa (664_CR12) 2017; 277 Y Takagi (664_CR9) 2011; 4 JS Schroeder (664_CR6) 1977; 40 K Ohkubo (664_CR21) 2008; 101 B Dorcely (664_CR24) 2021; 17 |
| References_xml | – ident: CR18 – volume: 101 start-page: 1519 issue: 10 year: 2008 ident: CR21 article-title: Do not forget vasospastic angina in patients with chest pain at rest and no significant coronary stenosis with multidetector computed tomography publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2007.12.018 – volume: 22 year: 2021 ident: CR25 article-title: Life-threatening complications related to delayed diagnosis of euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a report of 2 cases publication-title: Am J Case Rep doi: 10.12659/AJCR.929773 – volume: 12 start-page: 883 issue: 4 year: 1988 end-page: 888 ident: CR10 article-title: Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(88)90449-4 – volume: 17 start-page: 243 issue: 2 year: 2021 end-page: 246 ident: CR24 article-title: A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet publication-title: Curr Diabetes Rev doi: 10.2174/1573399816666200316112709 – volume: 46 start-page: S140 issue: Suppl 1 year: 2023 end-page: S157 ident: CR1 article-title: 9 Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023 publication-title: Diabetes Care doi: 10.2337/dc23-S009 – volume: 46 start-page: e772 issue: 8 year: 2018 end-page: e778 ident: CR15 article-title: Reversible microvascular hyporeactivity to acetylcholine during diabetic ketoacidosis publication-title: Crit Care Med doi: 10.1097/CCM.0000000000003224 – volume: 44 start-page: 157 year: 2021 end-page: 160 ident: CR4 article-title: Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management publication-title: Am J Emerg Med doi: 10.1016/j.ajem.2021.02.015 – volume: 45 start-page: 2718 issue: 11 year: 2022 end-page: 2728 ident: CR11 article-title: SGLT2 Inhibition, choline metabolites, and cardiometabolic diseases: a mediation mendelian randomization study publication-title: Diabetes Care doi: 10.2337/dc22-0323 – volume: 80 start-page: 289 issue: 2 year: 2016 end-page: 298 ident: CR22 article-title: The who, what, why, when, how and where of vasospastic angina publication-title: Circ J doi: 10.1253/circj.CJ-15-1202 – volume: 51 start-page: 2 issue: 1 year: 2008 end-page: 17 ident: CR17 article-title: Coronary artery spasm–clinical features, diagnosis, pathogenesis, and treatment publication-title: J Cardiol doi: 10.1016/j.jjcc.2008.01.001 – volume: 7 start-page: 291 issue: 6 year: 2015 end-page: 294 ident: CR5 article-title: Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis publication-title: N Am J Med Sci doi: 10.4103/1947-2714.157490 – volume: 58 start-page: 56 issue: 1 year: 1978 end-page: 62 ident: CR20 article-title: Coronary arterial spasm and prinzmetal’s variant form of angina induced by hyperventilation and tris-buffer infusion publication-title: Circulation doi: 10.1161/01.cir.58.1.56 – volume: 17 start-page: 23 issue: 1 year: 2017 ident: CR13 article-title: Assessment of platelets morphological changes and serum butyrylcholinesterase activity in children with diabetic ketoacidosis: a case control study publication-title: BMC Endocr Disord doi: 10.1186/s12902-017-0174-6 – volume: 124 start-page: 1774 issue: 16 year: 2011 end-page: 1782 ident: CR7 article-title: Mechanisms of coronary artery spasm publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.037283 – volume: 373 start-page: 2117 issue: 22 year: 2015 end-page: 2128 ident: CR2 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 40 start-page: 487 issue: 4 year: 1977 end-page: 491 ident: CR6 article-title: Provocation of coronary spasm with ergonovine maleate new test with results in 57 patients undergoing coronary arteriography publication-title: Am J Cardiol doi: 10.1016/0002-9149(77)90060-1 – volume: 4 start-page: 295 issue: 3 year: 2011 end-page: 302 ident: CR9 article-title: Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the japanese coronary spasm association publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.110.959809 – volume: 112 start-page: 44 issue: 1 year: 2019 end-page: 55 ident: CR8 article-title: Vasospastic angina: a literature review of current evidence publication-title: Arch Cardiovasc Dis doi: 10.1016/j.acvd.2018.08.002 – volume: 74 start-page: 955 issue: 5 year: 1986 end-page: 963 ident: CR14 article-title: Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm publication-title: Circulation doi: 10.1161/01.cir.74.5.955 – volume: 15 start-page: 56 issue: 2 year: 2017 end-page: 60 ident: CR23 article-title: Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis publication-title: J Cardiol Cases doi: 10.1016/j.jccase.2016.10.006 – volume: 277 start-page: 195 year: 2017 end-page: 203 ident: CR12 article-title: Canagliflozin prevents scopolamine-induced memory impairment in rats: comparison with galantamine hydrobromide action publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2017.08.013 – volume: 255 start-page: 291 issue: 4 year: 2021 end-page: 296 ident: CR19 article-title: Tubular injury causing protracted glycosuria following withdrawal of a sodium-glucose cotransporter 2 (SGLT2) inhibitor: a possible role in the development of protracted hypoglycemia and ketoacidosis publication-title: Tohoku J Exp Med doi: 10.1620/tjem.255.291 – volume: 11 start-page: 927 issue: 3 year: 2022 end-page: 940 ident: CR3 article-title: Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis publication-title: J Family Med Prim Care doi: 10.4103/jfmpc.jfmpc_644_21 – volume: 141 start-page: 479 issue: Suppl year: 1983 end-page: 483 ident: CR16 article-title: A critical level of diabetic autonomic neuropathy publication-title: Tohoku J Exp Med doi: 10.1620/tjem.141.suppl_479 – volume: 373 start-page: 2117 issue: 22 year: 2015 ident: 664_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 101 start-page: 1519 issue: 10 year: 2008 ident: 664_CR21 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2007.12.018 – volume: 74 start-page: 955 issue: 5 year: 1986 ident: 664_CR14 publication-title: Circulation doi: 10.1161/01.cir.74.5.955 – volume: 17 start-page: 23 issue: 1 year: 2017 ident: 664_CR13 publication-title: BMC Endocr Disord doi: 10.1186/s12902-017-0174-6 – volume: 141 start-page: 479 issue: Suppl year: 1983 ident: 664_CR16 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.141.suppl_479 – volume: 255 start-page: 291 issue: 4 year: 2021 ident: 664_CR19 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.255.291 – volume: 22 year: 2021 ident: 664_CR25 publication-title: Am J Case Rep doi: 10.12659/AJCR.929773 – volume: 15 start-page: 56 issue: 2 year: 2017 ident: 664_CR23 publication-title: J Cardiol Cases doi: 10.1016/j.jccase.2016.10.006 – volume: 51 start-page: 2 issue: 1 year: 2008 ident: 664_CR17 publication-title: J Cardiol doi: 10.1016/j.jjcc.2008.01.001 – volume: 46 start-page: S140 issue: Suppl 1 year: 2023 ident: 664_CR1 publication-title: Diabetes Care doi: 10.2337/dc23-S009 – volume: 277 start-page: 195 year: 2017 ident: 664_CR12 publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2017.08.013 – volume: 112 start-page: 44 issue: 1 year: 2019 ident: 664_CR8 publication-title: Arch Cardiovasc Dis doi: 10.1016/j.acvd.2018.08.002 – volume: 4 start-page: 295 issue: 3 year: 2011 ident: 664_CR9 publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.110.959809 – volume: 45 start-page: 2718 issue: 11 year: 2022 ident: 664_CR11 publication-title: Diabetes Care doi: 10.2337/dc22-0323 – volume: 12 start-page: 883 issue: 4 year: 1988 ident: 664_CR10 publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(88)90449-4 – volume: 11 start-page: 927 issue: 3 year: 2022 ident: 664_CR3 publication-title: J Family Med Prim Care doi: 10.4103/jfmpc.jfmpc_644_21 – volume: 124 start-page: 1774 issue: 16 year: 2011 ident: 664_CR7 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.037283 – volume: 44 start-page: 157 year: 2021 ident: 664_CR4 publication-title: Am J Emerg Med doi: 10.1016/j.ajem.2021.02.015 – volume: 46 start-page: e772 issue: 8 year: 2018 ident: 664_CR15 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000003224 – volume: 7 start-page: 291 issue: 6 year: 2015 ident: 664_CR5 publication-title: N Am J Med Sci doi: 10.4103/1947-2714.157490 – volume: 80 start-page: 289 issue: 2 year: 2016 ident: 664_CR22 publication-title: Circ J doi: 10.1253/circj.CJ-15-1202 – volume: 40 start-page: 487 issue: 4 year: 1977 ident: 664_CR6 publication-title: Am J Cardiol doi: 10.1016/0002-9149(77)90060-1 – volume: 17 start-page: 243 issue: 2 year: 2021 ident: 664_CR24 publication-title: Curr Diabetes Rev doi: 10.2174/1573399816666200316112709 – volume: 58 start-page: 56 issue: 1 year: 1978 ident: 664_CR20 publication-title: Circulation doi: 10.1161/01.cir.58.1.56 – ident: 664_CR18 doi: 10.1002/9781119309642.ch13 |
| SSID | ssj0000491076 |
| Score | 2.2727191 |
| Snippet | Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 135 |
| SubjectTerms | Acetylcholine Angina Angiography Arteriosclerosis Case Report Chest Coronary artery Coronary vessels Diabetes Diabetes mellitus (non-insulin dependent) Diagnosis Endocrinology Glucose Glucose transporter Ketoacidosis Ketones Medicine Medicine & Public Health Metabolic Diseases Nutrient deficiency Pain Sodium-glucose cotransporter Stenosis Trinucleotide repeats Vasoconstriction |
| Title | Life-threatening coronary vasospasm in patients with type 2 diabetes with SGLT2 inhibitor-induced euglycemic ketoacidosis: a report of two consecutive cases |
| URI | https://link.springer.com/article/10.1007/s13340-023-00664-8 https://www.ncbi.nlm.nih.gov/pubmed/38264228 https://www.proquest.com/docview/2917291065 https://www.proquest.com/docview/2918196798 https://pubmed.ncbi.nlm.nih.gov/PMC10800321 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BKyEuiPJMaSsjcQNLie0kDrcV6kPQcqErlVPk2I42QiRok6Xqf-mP7Uweu1oKBw65JBM70Xg83zwN8A4RfKJ9GnGdhSFXupDcGBPzSCAcD31YxIIKnC--Jmdz9fkqvhqLwtop230KSfY79abYTUpKRRSSk55UXD-E3RhtdxLHuZitPSuIedGm6U-VozrpCLfjsVrm78Nsa6R7MPN-tuQfIdNeE508hScjhGSzged78MDXz-DRxRgkfw6351XpebcgOOjJ7cEstSkwyxv227QNbiHtT1bVbGyp2jLyxTLyxTLBJl_scPPb6fmlQNpFVaDkLzka8LgUHPOIum8s5dWzH75rjK1c01btR2bYEIRgTcm66wZnrltvV7SnMosKs30B85Pjy09nfDyEgVsEUx33gprQF2mWlTEqM2UUQioVh4mOi8i6REXWCxs673VRijJF-yNxNktUoVOXKSlfwk7d1P41MNSEvrT4LtpIqpTOyDQucRAhMucQqQbwfmJE_mvotZFvuioT23JkW96zLdcBHEy8yke5a3OB1ideiKsCeLt-jBJDYRBT-2bV0yAMouhTAK8G1q6nk2htUVO0APQW09cE1I17-0ldLfqu3JSsGUoRBfBhWh-b7_r3b-z_H_kbeIxLXg1OoAPY6ZYrf4iwqCuOYHd2-v3L8VEvDXfP6QbN |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB7BIgEXxJvAAkbiBpYS20kcbivEUqDdC620t8hxHDVakaA6Be1_4ccyk0ersnDgkEsysRONx_PN0wCvEcEn2qUR11kYcqULyY0xMY8EwvHQhUUsqMB5cZbMVurzeXw-FoX5Kdt9Ckn2O_W-2E1KSkUUkpOeVFxfhxsIBjSdW7ASJzvPCmJetGn6U-WoTjrC7Xislvn7MIca6QrMvJot-UfItNdEp3fhzggh2cnA83twzTX34eZiDJI_gF_zunK8WxMcdOT2YJbaFJjNJfthfItbiP_G6oaNLVU9I18sI18sE2zyxQ43v36cLwXSrusCJX_D0YDHpVAyh6j70lJePbtwXWtsXba-9u-YYUMQgrUV6362OHPjnd3SnsosKkz_EFanH5bvZ3w8hIFbBFMdd4Ka0BdpllUxKjNlFEIqFYeJjovIlomKrBM2LJ3TRSWqFO2PpLRZogqdlpmS8hEcNW3jngBDTegqi--ijaQqWRqZxhUOIkRWlohUA3gzMSL_PvTayPddlYltObIt79mW6wCOJ17lo9z5XKD1iRfiqgBe7R6jxFAYxDSu3fY0CIMo-hTA44G1u-lwNSXUFC0AfcD0HQF14z580tTrvis3JWuGUkQBvJ3Wx_67_v0bT_-P_CXcmi0X83z-6ezLM7gtEGINDqFjOOo2W_ccIVJXvOgl4jcbSggs |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkSouqDwbWsBI3MBqYjuv3qrCUmBbIdGVeosc29FGiKTaZFv1v_Bjmcljl6Vw4JBL4rw09sw3r88AbxDBR4mLA56kvs9VkkuutQ55IBCO-87PQ0ENzqdn0clMfb4IL37r4u-q3ceUZN_TQCxNVXtwaYuDdeOblFSWKCQnm6l4chfuoToOaKbPxNEqyoL4F_2bboc56pkOUDUPnTN_f8ymdboFOW9XTv6RPu2s0mQHHgxwkh318n8Id1z1CLZPh4T5Y_g5LQvH2zlBQ0chEGaIskAvbtiVbmpUJ80PVlZsoFdtGMVlGcVlmWBjXLY_-e3j9Fzg2HmZoxZYcHTmcVpY5hCB3xiqsWffXVtrU9q6KZtDplmfkGB1wdrrGt9cNc4sSb8yg8azeQKzyYfz4xM-bMjADQKrljtBhPR5nKZFiIZNaYXwSoV-lIR5YGykAuOE8a1zSV6IIkZfJLImjVSexDZVUj6Fraqu3C4wtIquMHgv-kuqkFbLOCzwIUKk1iJq9eDtKIjssufdyNYMyyS2DMWWdWLLEg_2R1llwxpsMoGeKB6IsTx4vbqMq4dSIrpy9bIbg5CIMlEePOtFu3qdRM-LCNI8SDaEvhpAzNybV6py3jF0U-GmL0Xgwbtxfqy_69-_8fz_hr-C7a_vJ9n009mXPbgvEG31saF92GoXS_cC0VKbv-wWxC8Bzwxo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Life-threatening+coronary+vasospasm+in+patients+with+type+2+diabetes+with+SGLT2+inhibitor-induced+euglycemic+ketoacidosis%3A+a+report+of+two+consecutive+cases&rft.jtitle=Diabetology+international&rft.au=Kawahara%2C+Junko&rft.au=Kaku%2C+Bunji&rft.au=Yagi%2C+Kunimasa&rft.au=Kitagawa%2C+Naotaka&rft.date=2024-01-01&rft.issn=2190-1678&rft.volume=15&rft.issue=1&rft.spage=135&rft_id=info:doi/10.1007%2Fs13340-023-00664-8&rft_id=info%3Apmid%2F38264228&rft.externalDocID=38264228 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-1678&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-1678&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-1678&client=summon |